Evidence map›Paper›PMID 26060223›Full record

ArticleJournal of oncology practice2015

Use of Bevacizumab in Community Settings: Toxicity Profile and Risk of Hospitalization in Patients With Advanced Non-Small-Cell Lung Cancer.

Nikki M Carroll, Thomas Delate, Alex Menter, Mark C Hornbrook, Lawrence Kushi, Erin J Aiello Bowles, Elizabeth T Loggers, Debra P Ritzwoller

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of oncology practice, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Observational
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Nikki M CarrollKaiser Permanente Colorado, Denver, CO; Kaiser Permanente Northwest, Portland, OR; Kaiser Permanente Northern California, Oakland, CA; The Group Health Research Institute; and Fred Hutchinson Cancer Research Center, Seattle, WA Nikki.M.Carroll@kp.org.
Thomas DelateKaiser Permanente Colorado, Denver, CO; Kaiser Permanente Northwest, Portland, OR; Kaiser Permanente Northern California, Oakland, CA; The Group Health Research Institute; and Fred Hutchinson Cancer Research Center, Seattle, WA.
Alex MenterKaiser Permanente Colorado, Denver, CO; Kaiser Permanente Northwest, Portland, OR; Kaiser Permanente Northern California, Oakland, CA; The Group Health Research Institute; and Fred Hutchinson Cancer Research Center, Seattle, WA.
Mark C HornbrookKaiser Permanente Colorado, Denver, CO; Kaiser Permanente Northwest, Portland, OR; Kaiser Permanente Northern California, Oakland, CA; The Group Health Research Institute; and Fred Hutchinson Cancer Research Center, Seattle, WA.
Lawrence KushiKaiser Permanente Colorado, Denver, CO; Kaiser Permanente Northwest, Portland, OR; Kaiser Permanente Northern California, Oakland, CA; The Group Health Research Institute; and Fred Hutchinson Cancer Research Center, Seattle, WA.
Erin J Aiello BowlesKaiser Permanente Colorado, Denver, CO; Kaiser Permanente Northwest, Portland, OR; Kaiser Permanente Northern California, Oakland, CA; The Group Health Research Institute; and Fred Hutchinson Cancer Research Center, Seattle, WA.
Elizabeth T LoggersKaiser Permanente Colorado, Denver, CO; Kaiser Permanente Northwest, Portland, OR; Kaiser Permanente Northern California, Oakland, CA; The Group Health Research Institute; and Fred Hutchinson Cancer Research Center, Seattle, WA.
Debra P RitzwollerKaiser Permanente Colorado, Denver, CO; Kaiser Permanente Northwest, Portland, OR; Kaiser Permanente Northern California, Oakland, CA; The Group Health Research Institute; and Fred Hutchinson Cancer Research Center, Seattle, WA.

Funding

The HMO Cancer Research Network (CRN)U19CA079689 · NCI · KAISER FOUNDATION HEALTH PLAN OF WASHINGTON · PI MAZOR, KATHLEEN MICHELE · 1999 to 2011
$62.6M
CRN4: Cancer Research Resources & Collaboration in Integrated Health Care SystemsU24CA171524 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI KUSHI, LAWRENCE H · 2012 to 2016
$16.0M
Building CER Capacity: Aligning CRN, CMS, and State Resources to Map Cancer CareRC2CA148185 · NCI · DANA-FARBER CANCER INST · PI RITZWOLLER, DEBRA P, WEEKS, JANE C. · 2009 to 2009
$2.0M
NCI NIH HHS R01 CA113204NCI NIH HHS RC2 CA148185NCI NIH HHS U19 CA079689NCI NIH HHS U19 CA79689NCI NIH HHS U24 CA171524
6 · The paper itself

Abstract

purposeLittle is known regarding toxicities and hospitalizations in community-based settings for patients with advanced non-small-cell lung cancer (NSCLC) who received commonly prescribed carboplatin-paclitaxel (CP) or carboplatin-paclitaxel-bevacizumab (CPB) chemotherapy.

methodsPatients with stages IIIB-IV NSCLC age ≥ 21 years diagnosed between 2005 and 2010 who received first-line CP or CPB were identified at four health maintenance organizations (N = 1,109). Using patient and tumor characteristics and hospital and ambulatory encounters from automated data in the 180 days after chemotherapy initiation, the association between CP and CPB and toxicities and hospitalizations were evaluated with χ(2) tests and propensity score-adjusted regression models.

resultsPatients who received CPB were significantly younger and had significantly more bleeding, proteinuria, and GI perforation events (all P < .05). For these patients, the unadjusted odds ratio associated with the likelihood of having a hospitalization was 0.46 (95% CI, 0.32 to 0.67). As shown by multivariable and propensity score-adjusted models, patients who received CPB were less likely to have been hospitalized (odds ratio, 0.48; 95% CI, 0.32 to 0.71) and had fewer total hospitalizations (rate ratio, 0.62; 95% CI, 0.47 to 0.82) and hospital days (rate ratio, 0.53; 95% CI, 0.47 to 0.60) than patients who received CP.

conclusionConsistent with earlier randomized clinical trials, significantly more toxicity events were identified in patients treated with CPB. However, both unadjusted and adjusted models showed that patients who received CPB were less likely than patients who received CP to experience a hospital-related event after the initiation of chemotherapy. Findings here confirm the need for adherence to clinical recommendations for judicious use of CPB, but provide reassurance regarding the relative risk for hospitalizations.

Indexed as

AgedAngiogenesis InhibitorsBevacizumabCarcinoma, Non-Small-Cell LungCohort StudiesFemaleHospitalizationHumansLung NeoplasmsMaleMiddle AgedRetrospective StudiesRisk FactorsTreatment OutcomeAngiogenesis InhibitorsBevacizumab

Identifiers

PMID26060223
PMCPMC4575400

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.